Details for Patent: 10,772,888

✉ Email this page to a colleague

Which drugs does patent 10,772,888 protect, and when does it expire?

Patent 10,772,888 protects ISENTRESS HD and is included in one NDA.

This patent has thirty-three patent family members in twenty-six countries.

Summary for Patent: 10,772,888

Patent landscape, scope, and claims:

Title:	Solid pharmaceutical compositions containing an integrase inhibitor
Abstract:	Compressed tablets for oral administration containing raltegravir in the form of a pharmaceutically acceptable salt are described. The tablets comprise: (A) an intragranular component comprising (i) an effective amount of an alkali metal salt of raltegravir, (ii) optionally a first superdisintegrant, and (iii) a binder; and (B) an extragranular component comprising (i) a second superdisintegrant, (ii) a filler, and (iii) a lubricant. Methods for preparing the tablets and the use of the tablets, optionally in combination with other anti-HIV agents, for the inhibition of HIV integrase, for the treatment or prophylaxis of HIV infection, or for the treatment, delay in the onset, or prophylaxis of AIDS are also described.
Inventor(s):	Mahjour; Majid (Schwenksville, PA), Li; Feng (Dresher, PA), Ma; Decheng (Souderton, PA), Sotthivirat; Sutthilug (Lansdale, PA)
Assignee:	Merck Sharp & Dohme Corp. (Rahway, NJ)
Application Number:	15/483,030
Patent Claim Types: see list of patent claims	Use; Composition; Dosage form;
More… ↓ ⤷ Subscribe

Drugs Protected by US Patent 10,772,888

Glossary

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Msd Sub Merck	ISENTRESS HD	raltegravir potassium	TABLET;ORAL	022145-002	May 26, 2017		RX	Yes	Yes	10,772,888	⤷ Subscribe				TREATMENT OF HIV-1 INFECTION	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 10,772,888

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2010313571	⤷ Subscribe
Brazil	112012009857	⤷ Subscribe
Canada	2777937	⤷ Subscribe
China	102655752	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.